MRD outcomes from GLOW: venetoclax and ibrutinib in CLL VJHemOnc – Video Journal of Hematology & HemOnc 3:09 3 years ago 188 Далее Скачать
GLOW: Assessing ibrutinib plus venetoclax in CLL VJHemOnc – Video Journal of Hematology & HemOnc 1:54 2 years ago 364 Далее Скачать
Achieving undetectable MRD with ibrutinib plus venetoclax for CLL VJHemOnc – Video Journal of Hematology & HemOnc 1:53 3 years ago 219 Далее Скачать
Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax VJHemOnc – Video Journal of Hematology & HemOnc 2:43 1 year ago 621 Далее Скачать
Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-line treatment of C... ecancer 5:49 2 years ago 25 Далее Скачать
The GLOW study: MRD kinetics among patients with high-risk factors treated with Ibr+Ven versus Clb+O VJHemOnc – Video Journal of Hematology & HemOnc 1:27 1 year ago 104 Далее Скачать
FLAIR trial: improved outcomes with MRD-guided ibrutinib plus venetoclax in CLL compared to FCR VJHemOnc – Video Journal of Hematology & HemOnc 3:00 1 year ago 365 Далее Скачать
Driver mutations predicting clinical outcomes upon MRD-guided venetoclax plus ibrutinib in R/R CLL VJHemOnc – Video Journal of Hematology & HemOnc 1:50 4 days ago 34 Далее Скачать
Interim analysis of the FLAIR study: efficacy of ibrutinib plus venetoclax in IgHV unmutated CLL VJHemOnc – Video Journal of Hematology & HemOnc 1:23 1 year ago 328 Далее Скачать
ASH CLL highlights: ibrutinib-venetoclax combination & undetectable MRD in IGHV-mutated patients VJHemOnc – Video Journal of Hematology & HemOnc 1:47 2 years ago 536 Далее Скачать
CAPTIVATE: Ibrutinib and venetoclax in CLL VJHemOnc – Video Journal of Hematology & HemOnc 2:21 2 years ago 371 Далее Скачать
GLOW trial: Is fixed duration ibrutinib + venetoclax a feasible frontline treatment option for CLL? Lymphoma Hub 6:15 3 years ago 176 Далее Скачать
MRD-driven addition of ibrutinib to venetoclax for CLL VJHemOnc – Video Journal of Hematology & HemOnc 2:36 3 years ago 115 Далее Скачать
The impact of MRD & genetics on outcomes to time-limited combinations in patients with CLL VJHemOnc – Video Journal of Hematology & HemOnc 0:55 2 years ago 107 Далее Скачать
GLOW: primary analysis of ibrutinib plus venetoclax versus obinutuzumab plus chlorambucil in CLL VJHemOnc – Video Journal of Hematology & HemOnc 3:34 3 years ago 206 Далее Скачать
First-line ibrutinib and venetoclax in CLL VJHemOnc – Video Journal of Hematology & HemOnc 2:18 2 years ago 350 Далее Скачать
UK NCRI FLAIR trial: ibrutinib + venetoclax with MRD-directed duration of treatment in CLL VJHemOnc – Video Journal of Hematology & HemOnc 2:17 10 months ago 212 Далее Скачать
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status VJHemOnc – Video Journal of Hematology & HemOnc 2:28 1 year ago 147 Далее Скачать
AVO achieves high rates of undetectable MRD in CLL VJHemOnc – Video Journal of Hematology & HemOnc 3:29 3 years ago 331 Далее Скачать
ERADIC trial: preliminary results of MRD-guided ibrutinib plus venetoclax vs FCR VJHemOnc – Video Journal of Hematology & HemOnc 1:43 1 year ago 75 Далее Скачать
